Drugs / NCS-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03915431 | Feb 2020 → Oct 2027 expected | ischemic stroke | NC Medial Research Inc | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCS-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03915431 ↗ |
| Modality | Cell therapy | “human bone marrow derived cells” NCT03915431 ↗ |
| Route | Other | “Intracarotid Artery Administration” NCT03915431 ↗ |